Roche
www.roche.com.sg
Some information on this page may be available only to Healthcare Professionals. Please

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The biotech giant offers differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also a global leader in in vitro diagnostics and tissue-based cancer diagnostics, and a front-runner in diabetes management.​

Founded in 1896, the company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than 30 medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. The Roche Group, headquartered in Basel, Switzerland, has had a presence in Singapore since 1973.

Branches

1

Roche Singapore Pte Ltd

1 Paya Lebar Link, #09-03 PLQ 1, Paya Lebar Quarter, Singapore 408533​

Key Trials

4 trials shown

Roche

Key trial

A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

This study will evaluate the efficacy of tiragolumab plus atezolizumab and carboplatin and etoposide (CE) compared with placebo plus atezolizumab and CE in participan

Study number:
NCT04256421
Cohorts:
1
Study phase:
3
Overall status:
Recruiting
Study type:
Immunotherapy, Chemotherapy

Roche

Key trial

A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer

This study will evaluate the efficacy, safety, and pharmacokinetics of inavolisib in combination with palbociclib and fulvestrant compared with placebo plus palbociclib and fulvest

Study number:
NCT04191499
Cohorts:
1
Study phase:
2, 3
Overall status:
Recruiting
Study type:
Targeted therapy, Biomarker, Hormonal therapy

Roche

Key trial

A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation

This study will evaluate the efficacy and safety of adjuvant therapy with atezolizumab plus bevacizumab compared with active surveillance in participants with completely resected o

Study number:
NCT04102098
Cohorts:
1
Study phase:
3
Overall status:
Active, not recruiting
Study type:
Immunotherapy, Targeted therapy

Roche

Key trial

Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors

This is a first-in-human, open-label, multicenter, Phase I multiple-ascending dose (MAD) study of RO7247669, an anti PD-1 (programmed death-1) and LAG-3 (Lymphocyte-activation gene

Study number:
NCT04140500
Cohorts:
1
Study phase:
1, 2
Overall status:
Recruiting
Study type:
Immunotherapy, Targeted therapy